358 related articles for article (PubMed ID: 17967843)
21. Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis.
Serarslan G; Okuyucu E; Melek I; Hakverdi S; Duman T
Mult Scler; 2008 Mar; 14(2):259-61. PubMed ID: 18337427
[TBL] [Abstract][Full Text] [Related]
22. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C
Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767
[TBL] [Abstract][Full Text] [Related]
23. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis.
Uzawa A; Mori M; Hayakawa S; Masuda S; Kuwabara S
Eur J Neurol; 2010 May; 17(5):672-6. PubMed ID: 20039942
[TBL] [Abstract][Full Text] [Related]
24. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
Etemadifar M; Janghorbani M; Shaygannejad V
Acta Neurol Scand; 2006 May; 113(5):283-7. PubMed ID: 16629762
[TBL] [Abstract][Full Text] [Related]
26. Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS).
Gottesman MH; Friedman-Urevich S
Mult Scler; 2006 Jun; 12(3):271-80. PubMed ID: 16764339
[TBL] [Abstract][Full Text] [Related]
27. A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis.
Jaber A; Bozzato GB; Vedrine L; Prais WA; Berube J; Laurent PE
BMC Neurol; 2008 Oct; 8():38. PubMed ID: 18845005
[TBL] [Abstract][Full Text] [Related]
28. [Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices].
Brochet B; Lemaire G; Beddiaf A;
Rev Neurol (Paris); 2006 Jun; 162(6-7):735-40. PubMed ID: 16840982
[TBL] [Abstract][Full Text] [Related]
29. Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis.
Bitsch A; Bahner D; Wachter C; Elitok E; Bogumil T; Dressel A; Polak T; Tumani H; Weber F; Poser S; Kitze B
Acta Neurol Scand; 2004 Dec; 110(6):386-92. PubMed ID: 15527451
[TBL] [Abstract][Full Text] [Related]
30. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Picconi O; Cilia S; Cottone S; Centonze D; Gasperini C;
Mult Scler; 2011 Aug; 17(8):991-1001. PubMed ID: 21502310
[TBL] [Abstract][Full Text] [Related]
31. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL;
Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
[TBL] [Abstract][Full Text] [Related]
32. Interferon beta-1A: new preparation. A short-term impact on the course of multiple sclerosis.
Prescrire Int; 1998 Oct; 7(37):142-3. PubMed ID: 10915418
[TBL] [Abstract][Full Text] [Related]
33. Long-term interferon-beta treatment for multiple sclerosis.
Ruggieri RM; Settipani N; Viviano L; Attanasio M; Giglia L; Almasio P; La Bella V; Piccoli F
Neurol Sci; 2003 Dec; 24(5):361-4. PubMed ID: 14716534
[TBL] [Abstract][Full Text] [Related]
34. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sørensen PS; Christensen T; Frederiksen J; Ravnborg M; Jensen K; Heltberg A; Kristensen O; Stenager E; Petersen T; Hansen T;
Neurology; 2006 Apr; 66(7):1056-60. PubMed ID: 16510769
[TBL] [Abstract][Full Text] [Related]
35. [Interferon therapy of multiple sclerosis].
Jensen D
Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481
[TBL] [Abstract][Full Text] [Related]
36. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
Nakamura Y; Kawachi Y; Furuta J; Otsuka F
Eur J Dermatol; 2008; 18(5):579-82. PubMed ID: 18693165
[TBL] [Abstract][Full Text] [Related]
37. [Interferon-beta 1a in relapsing-remitting multiple sclerosis. First report of a Mexican population].
León C; Violante A; Arriada N; Santana HR; Corona T
Rev Neurol; 2000 Dec 1-15; 31(11):1019-22. PubMed ID: 11190865
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
39. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.
Ross C; Clemmesen KM; Svenson M; Sørensen PS; Koch-Henriksen N; Skovgaard GL; Bendtzen K
Ann Neurol; 2000 Nov; 48(5):706-12. PubMed ID: 11079533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
